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Background: Progranulin (PGRN), a widely secreted growth factor, is involved in multiple biological functions, and
mutations located within the PGRN gene (GRN) are a major cause of frontotemporal lobar degeneration with TDP-
43-positive inclusions (FLTD-TDP). In light of recent reports suggesting PGRN functions as a protective neurotrophic
factor and that sortilin (SORT1) is a neuronal receptor for PGRN, we used a Sort1-deficient (Sort1−/−) murine primary
hippocampal neuron model to investigate whether PGRN’s neurotrophic effects are dependent on SORT1. We
sought to elucidate this relationship to determine what role SORT1, as a regulator of PGRN levels, plays in
modulating PGRN’s neurotrophic effects.
Results: As the first group to evaluate the effect of PGRN loss in Grn knockout primary neuronal cultures, we show
neurite outgrowth and branching are significantly decreased in Grn−/− neurons compared to wild-type (WT)
neurons. More importantly, we also demonstrate that PGRN overexpression can rescue this phenotype. However,
the recovery in outgrowth is not observed following treatment with recombinant PGRN harboring missense
mutations p.C139R, p.P248L or p.R432C, indicating that these mutations adversely affect the neurotrophic properties
of PGRN. In addition, we also present evidence that cleavage of full-length PGRN into granulin peptides is required
for increased neuronal outgrowth, suggesting that the neurotrophic functions of PGRN are contained within certain
granulins. To further characterize the mechanism by which PGRN impacts neuronal morphology, we assessed the
involvement of SORT1. We demonstrate that PGRN induced-outgrowth occurs in the absence of SORT1 in Sort1−/−
cultures.
Conclusion: We demonstrate that loss of PGRN impairs proper neurite outgrowth and branching, and that
exogenous PGRN alleviates this impairment. Furthermore, we determined that exogenous PGRN induces outgrowth
independent of SORT1, suggesting another receptor(s) is involved in PGRN induced neuronal outgrowth.
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Frontotemporal lobar degeneration (FTLD) is the second-
most common presenile dementia after Alzheimer’s dis-
ease (AD) [1]. FTLD is neuropathologically characterized
by predominant atrophy of the frontal and temporal lobes
and the presence of proteinaceous inclusions in neurons
and glial cells [2]. FTLD cases are divided into two main
pathological subgroups at autopsy: those with tau-positive
inclusions (FTLD-tau), and those with TDP-43-positive
inclusions (FTLD-TDP) [3].* Correspondence: petrucelli.leonard@mayo.edu
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reproduction in any medium, provided the orIn 2006, mutations located within GRN, were described
as a major cause of FTLD-TDP [4,5]. Pathogenic muta-
tions in GRN mainly include frameshift, splice site and
nonsense mutations that produce a premature termin-
ation of the coding sequence and consequently lead to
degradation of mutant mRNA via nonsense-mediated
decay [4-6]. As a result, pathogenic mutations are thought
to cause disease by GRN haploinsufficiency. With the ex-
ception of the pathogenic missense mutation p.A9D,
which prevents PGRN secretion, it is not known whether
missense mutations in GRN influence PGRN’s neuro-
trophic properties [6,7].
PGRN is a widely expressed secreted growth factor
involved in development, wound repair and inflammationd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protective neurotrophic factor; however, its role in the
CNS is not well understood [10-13]. The mechanisms
underlying its effects have not been fully determined, nor
is it known how missense mutations in GRN influence its
neurotrophic properties.
The protein contains seven-and-a-half tandem repeats
of a 12-cysteine granulin motif separated by interlinked
spacer regions that are termed granulins [14]. In the
periphery, full-length PGRN is proteolytically cleaved
into mature granulins via proteases [15,16]. Secretory
leukocyte protease inhibitor (SLPI), a serine protease in-
hibitor, prevents PGRN cleavage by binding to PGRN
cleavage sites or to elastase and inhibiting its cleavage
activity [16].
Recently, two PGRN receptors have been identified:
sortilin 1 (SORT1) and tumor necorosis factor receptor
(TNFR) [17,18]. The neuronal PGRN receptor, SORT1,
has been shown to regulate the extracellular levels of
PGRN [17,19]. SORT1, a vacuolar protein sorting 10
protein domain receptor, is also involved in endocytosis
and transport of proteins to the trans-golgi network and
endosomes/lysosomes [20]. The C-terminal portion of
PGRN binds to SORT1 causing immediate endocytosis
of PGRN to the lysosome. Due to its interactions with
SORT1, we sought to determine whether PGRN utilizes
this receptor to modulate neuronal morphology. With
regard to the loss of PGRN leading to neurodegenera-
tion, we investigated the physiological impact/conse-
quences of loss of PGRN in primary hippocampal
neuronal cultures.Results
Loss of PGRN alters neuronal morphology
GRN haploinsufficiency due to mutations in GRN cause
FTLD-TDP [2]. To evaluate the impact of PGRN defi-
ciency on neuron morphology, primary hippocampal
cultures from WT and Grn−/− mice were prepared.
Western blot analysis confirmed the complete loss of
PGRN in hippocampal cultures from Grn−/− mice
(Figure 1A). In order to assess neuronal outgrowth, neu-
rons were fixed and immunostained using neuron-
specific anti-MAP2 following 10 days in vitro (DIV10).
Using confocal microscopy, we captured and analyzed
images using MetaMorph 7.1 software (Figure 1B),
which quantitatively measures total skeletonized out-
growth of individual neurons in μms and total branching
junctions of dendrites. As quantified in Figure 1C-E,
Grn−/− neurons displayed significantly reduced neurite
outgrowth (p< 0.0001) and branching (p< 0.005) com-
pared to WT neurons, while cell body size remained the
same. In all experiments, at least 100 neurons were ana-
lyzed and repeated in three independent experiments.Exogenous PGRN rescues neurite outgrowth and
branching in Grn−/− neurons
Having established that a loss of endogenous PGRN
causes major deficits in neurite outgrowth and branch-
ing of hippocampal neurons, we then examined whether
this phenotype can be rescued by returning PGRN to
cultures. To achieve PGRN overexpression in our cul-
tures, we packaged PGRN into a rAAV1 vector (rAAV1-
PGRN). Dosing titers are expressed genomes/mL.
To determine if we could rescue the Grn−/− phenotype,
we transduced primary hippocampal neurons with in-
creasing doses of rAAV1-PGRN for 6 days to allow for
synthesis of PGRN. Under normal conditions, our WT
primary culture’s Pgrn levels were around 4 ng/mL
(Figure 2A). In testing for the production and release of
PGRN into the media, human specific ELISA revealed a
dose-dependent increase of PGRN secreted into the
medium (Figure 2B). Neuronal morphology was then
assessed in Grn−/− and WT neurons treated with the same
increasing titers of rAAV1-PGRN. Application of rAAV1-
PGRN resulted in statistically significant increased out-
growth and branching in both Grn−/− and WT cultures
(Figure 2C-F). rAAV1-GFP transduction in cultures did
not promote outgrowth or branching, suggesting that the
production of PGRN induces outgrowth and plays a role
in neuronal morphology. All conditions were normalized
to WT rAAV1-GFP treated cells revealing that the pheno-
type was rescued at a rAAV1-PGRN titer of 1011 gen-
omes/mL or 14 ng/mL within the media.
rPGRN promotes neuronal outgrowth and branching in
Grn−/− and WT cultures
Since determining that exogenous overexpression of
rAAV1-PGRN is able to rescue the Grn−/− neuronal
phenotype, we purified recombinant human PGRN
(rPGRN) from media of a stable HEK 293 cell line over-
expressing PGRN. The rPGRN was then applied to WT
and Grn−/− cultures in increasing doses. The results
from this experiment show a dose-dependent, significant
increase in outgrowth and branching in Grn−/− neurons
as well as WT neurons (Figure 3A-D). These results also
reveal that 125 nM (10 ug/mL) rPGRN is needed to res-
cue the Grn−/− phenotype and return outgrowth and
branching to normal conditions.
Cleavage of PGRN promotes neuronal outgrowth
PGRN is secreted as a full-length 88 kDa protein, which is
cleaved into mature granulins. In fact, Western blot ana-
lysis of rPGRN treated cultures shows rPGRN cleavage
within cultures (Figure 3E). Note that in the media,
rPGRN becomes cleaved into granulin fragments within 1
hour. To determine whether PGRN or granulins are re-
sponsible for inducing neurite outgrowth, WT cultures
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Figure 1 Loss of Pgrn decreases neurite outgrowth and branching in primary neurons. (A) Western blot analysis reveals endogenous levels
of Pgrn in WT and Grn−/− primary hippocampal cultures. (B) WT and Grn−/− hippocampal neurons immunostained for MAP2. (C-E). Neurite
outgrowth and branching of MAP2-immunopositive neurons was assessed using MetaMorph version 7.1 software. Note that neurite outgrowth
(C) and branching (D), but not cell body size (E), are decreased in Grn−/− hippocampal neurons compared to WT hippocampal neurons. All data
is presented as the mean± SEM. **p< 0.01; ***p< 0.001.
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izing an elastase digest assay, we first confirmed that rSLPI
prevents processing of rPGRN into GRNs (Figure 4A).
Upon incubation of rPGRN with elastase, PGRN cleavage
occurred within 5 minutes; however, when rSLPI was
added, the cleavage of PGRN by elastase was inhibited.
We sought to examine rSLPI’s effects on endogenous
mouse Pgrn levels, which had yet to be determined.
After treating WT cultures expressing endogenous Pgrn
with rSLPI, we observed reduced outgrowth (Figure 4B)
and branching (Figure 4C) similar to untreated Grn−/−
cultures. When rSLPI was added to Grn−/− cultures
there was no change in outgrowth or branching, illus-
trating that rSLPI is targeting PGRN and that PGRN
cleavage is required to induce outgrowth. While treat-
ment with rPGRN alone increases outgrowth, co-
treatment of rSLPI and rPGRN in WT neurons does not
increase outgrowth (Additional file 1: Figure S1).
These findings next led us to investigate the neuro-
trophic activity of specific granulins. Here, neurons were
treated with recombinant granulin protein containing
full length PGRN, and commercially available granulin E
(rGRN E) or granulin C (rGRN C) (Figure 4D). Treat-
ment with granulins E and C (125 nM/10 ug/mL) pro-
moted neuronal outgrowth very similar to PGRN
treatment (125 nM/10 ug/mL) suggesting these granulin
species harbor neurotrophic properties (Figure 4E).
C-terminal tag inhibits SORT1 uptake and PGRN
endocytosis
SORT1 was recently identified as a neuronal receptor for
PGRN; however, its role in PGRN function is not wellunderstood. We decided to test recombinant PGRN
(rPGRN) on N2A cells transduced to overexpress rAAV1-
SORT1 or rAAV1-GFP (Figure 5A). Human rPGRN was
generated from an HEK293 stable cell line containing a
His-tag located at either the N-terminal (His-rPGRN) or
C-terminal (rPGRN-His) region of rPGRN. Our results in-
dicate that overexpression of SORT1 triggers increased
uptake of His-rPGRN and not rPGRN-His, suggesting the
C-terminal tag inhibits PGRN’s ability to bind to SORT.
Since the binding of PGRN to SORT1 was hindered by
the C-terminal tag, we next compared the ability of His-
rPGRN and rPGRN-His to promote outgrowth and
branching in primary hippocampal cultures. We deter-
mined that both His-rPGRN and rPGRN-His were able to
equally induce outgrowth (Figure 5B).PGRN promotes neuronal outgrowth and branching
independent of Sortilin
We previously showed that SORT1 can regulate PGRN
levels, but to elucidate the role this receptor plays in
neurotrophic morphology, we examined Sort1−/− hippo-
campal cultures. Western blot analysis confirmed the
complete deletion of Sort1 in hippocampal cultures
(Figure 6A). Since Sort1 is involved in uptake of PGRN,
we then wanted to learn whether these cultures have a
marginal increase in secreted Pgrn. ELISA data from
WT and Sort1−/− cultures revealed increases of Pgrn in
Sort1−/− cultures compared to WT (Figure 6B). On
the other hand, neuronal outgrowth studies revealed
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Figure 2 Primary hippocampal cultures transduced with rAAV1-PGRN promotes neurite outgrowth and branching. (A) Mouse Pgrn ELISA
of endogenous Pgrn levels in hippocampal primary neuronal cultures. (B) Human PGRN ELISA shows increasing levels of hPGRN generated in the
media of treated primary cultures. (C,D) Bar graph quantification of total outgrowth (C) and branching (D)of primary hippocampal neurons
transduced with increasing amounts of rAAV1-PGRN in WT cultures normalized to WT rAAV1-GFP treated cultures. (E,F) Bar graph quantification
of normalized total outgrowth (E) and branching (F)in Grn−/− hippocampal neurons transduced with rAAV1-PGRN normalized to WT rAAV1-GFP
treated cultures. Note that rAAV1-GFP was supplemented in rAAV1-PGRN non-treated cultures. Data is presented as the mean± SEM.
*p< 0.05; ***p< 0.001.
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the absence of SORT1 and ultimately whether SORT1 is
a neurotrophic receptor for PGRN, we treated primary
hippocampal Sort1−/− and WT neurons with increasing
amounts of rPGRN. We found a dose-dependent in-
crease in outgrowth occurs in Sort1−/− neurons similar
to WT (Figure 6D, 6F). Additionally increased branchingof these neurons was also seen (Figure 6E, 6G), suggest-
ing PGRN does not use SORT1 to promote outgrowth.
Missense mutant PGRN alters neuronal morphology
While the majority of pathogenic GRN mutations lead to
the degradation of mutant mRNA and/or cause GRN






































































































































Figure 3 rPGRN promotes neurite outgrowth and branching in primary neurons. (A) (A,B) Bar graph quantification of total neurite
outgrowth (A) and branching (B) of WT hippocampal neurons exposed to rPGRN increasing 25, 125, 625 nM doses of His-rPGRN (nM doses
correspond to 2,10, 50 ug/mL concentrations respectively). All doses normalized to WT non-treated cultures. (C,D) Bar graph quantification of
normalized total neurite outgrowth (C) and branching (D) in of Grn−/− hippocampal neurons exposed to rPGRN. Grn−/− cultures were normalized
to WT non-treated cultures. (E) Western blot analysis reveals PGRN cleavage in Grn−/− hippocampal cultures treated with 125 nM rPGRN-His at
increasing time points. Note cleavage of PGRN after only one hour. Data is presented as the mean± SEM. **p< 0.01.
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secretion (p.R432C, p.P248L), when compared to WT
PGRN [7,21]. The p.S120Y GRN mutation has been
found in controls and believed to be non-pathogenic
[22]. To determine whether these missense mutations
also disrupt the neurotrophic function of PGRN, we gen-
erated recombinant PGRN proteins harboring the afore-
mentioned missense mutations (Figure 7A) and assessed
their effect on neurite outgrowth in Grn−/− neurons.
As expected, rPGRN containing p.S120Y, a mutation
observed in controls, promoted neurite outgrowth to a
similar extent as WT rPGRN (Figure 7B). In contrast,
rPGRN with p.C139R, p.R432C and p.P248L mutationsfailed to stimulate neurite outgrowth (Figure 7B),
suggesting these mutations disrupt PGRN function
and may indeed be pathogenic and contribute to the
disease phenotype observed in patients carrying these
mutations.
Discussion
While loss of PGRN is a major cause of FTLD-TDP, it
remains unclear how this loss leads to neurodegeneration.
Recent studies suggest that PGRN may function as a
protective neurotrophic factor regulating neuronal survival
and outgrowth in cortical/motor primary neurons, immor-
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Figure 4 PGRN processing promotes neuronal outgrowth and branching. (A) Time course analysis of rPGRN subjected to elastase digest.
PGRN cleavage products visualized by SDS-PAGE, post-stain with sypro ruby solution (Sigma). Note that the co-treatment of recombinant SLPI
blocks elastase-mediated rPGRN cleavage. (B,C) Bar graphs depict quantification of total neurite outgrowth (B) and branching (C) of WT and
Grn−/− neurons treated with or without rSLPI. Note that in these experiments no rPGRN was added, therefore rSLPI blocks endogenous Pgrn.
(D) Schematic representation of recombinant proteins analyzed in primary hippocampal neurons. (E) WT hippocampal cultures treated with
recombinant granulin E (rGRN E) and granulin C (rGRN C) promote outgrowth similar to full length PGRN Data is presented as the mean± SEM.
*p< 0.05; ***p< 0.001.
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fully determined, nor is it known how GRNmissense muta-
tions and SORT1, a PGRN neuronal receptor, influence
PGRN’s neurotrophic properties.
In the current study, we examined the effects of
PGRN loss in primary neuronal cultures from Grn−/−
mice. Our data show that neuronal outgrowth and
branching in Grn−/− primary cultures are significantly
reduced compared to WT cultures. We also demon-
strate that PGRN promotes neurite outgrowth independ-
ent of Sort1. Such findings advance our knowledge
beyond previous studies, and strongly suggest another re-
ceptor(s) modulates PGRN-specific neuronal outgrowth
and branching.
Since the discovery of the first GRN mutations, several
groups have developed various Grn−/− mouse models
[26-28]. While the murine models recapitulate several
pathological features of FTLD patients, such as increased
gliosis and TDP-43 positive inclusions, no two modelsare the same, likely due to different backgrounds strains
or strategies used to knockout Grn. For our experiments,
we used primary hippocampal cultures prepared from
Grn−/− mice generated by Kayasuga et al. [27], with the
knowledge that these mice display accelerated brain
aging due to increased accumulation of lipofuscin, in
addition to enhanced gliosis and neurodegeneration
when compared to WT mice [29]. These Grn−/− mice
also mimic behavior changes similar to FTLD patients,
including increased aggression, decreased social inter-
action and impaired learning and memory [27,30]. Even
though our mice display increased ubiquitin staining,
they are not positive for TDP-43, the neuropathological
hallmark of FTLD with GRN mutations. Yin et al devel-
oped a Grn−/− mouse displaying amplified inflammation
in addition to increased ubiquitin staining positive for
TDP-43 [26]. Increased TDP-43 accumulation is also
observed in Grn−/− neurons treated with the proteosome

















































Figure 5 SORT1 triggers endocytosis of rPGRN. (A) Western blot analysis of Neuro2A cells transduced with rAAV-GFP or rAAV-SORT1 in the
presense of His-rPGRN or rPGRN-His. Note uptake of His-rPGRN into cell lysates and the absence of rPGRN-His uptake. (B) Bar graph quantification
of WT primary neuronal cultures treated with increasing 25, 125, 625 nM doses of His-rPGRN or rPGRN-His depict equal amounts of outgrowth
with between treatments (nM doses correspond to 2, 10, 50 ug/mL concentrations respectively). Data is presented as the mean± SEM.
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haploinsufficiency cell culture models generated similar
results, where GRN knockdown using siRNA resulted in
TDP-43 cleavage; however, downregulation of GRN for
short time points does not produce TDP-43 cleavage
[32,33].
FTLD patients with GRN mutations develop severe at-
rophy of the frontal and temporal lobes of the brain
[34]. Therefore, understanding the role of PGRN in
neuronal health and function, as well as regulating levels
are important for future studies. Recent efforts using
Grn−/− mice have helped shed new light on the many
functions of PGRN. Petkau and colleagues determined
that Grn−/− mice have reduced synaptic connectivity and
altered LTP, in addition to altered morphology and
reduced spine density of apical dendrites of the hippo-
campus of aged mice [28]. Additional studies in neurons
with reduced GRN using siRNA revealed decreasedneuronal arborization and synaptic density in addition to
abnormal transmission at the synapses [31]. These find-
ings suggest that loss of PGRN alters morphology of
neurons leading to synaptic changes, which ultimately
may cause neurodegeneration.
To further characterize our mice, we compared WT
and Grn−/− cultures and found Grn−/− primary hippo-
campal neurons display significantly shorter neurites and
fewer branch points compared to WT neurons. Import-
antly, this phenotype is reversed when neurons are sup-
plemented with PGRN via recombinant or viral methods.
While rAAV1-PGRN transduction leads to the intracellu-
lar expression of PGRN, ELISA-based quantification of
PGRN from media indicated that extracellular PGRN
levels increase in a dose-dependent manner following
rAAV1-PGRN transduction. Normal physiological ranges
for human PGRN are approximately 100–400 ng/mL and

























































































































































































Figure 6 Pgrn induces outgrowth independent of Sort1. (A) Western blot analysis of Pgrn and Sort1 levels in WT and Sort1−/− hippocampal
cultures. (B) Mouse specific ELISA showing increasing levels of Pgrn in Sort1−/− culture media. (C) Bar graph quantification of normalized total
neurite outgrowth in Sort1−/− and WT cultures showing significant decreases in Sort1−/−. (D-G) Normalized total outgrowth (D,F) and total
branching (E,G) in Sort1−/− and WT cultures with increasing amounts of His-rPGRN treatment. Data is presented as the mean± SEM.
*p< 0.05; **p< 0.01.
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levels are approximately 3.5 ng/mL [32,33]. Increasing
doses of rAAV1-PGRN elevated exogenous PGRN levels
to 3-15 ng/ml. These studies demonstrate that rAAV1-
PGRN transduction resulting in 15 ng/mL PGRN within
the media, is sufficient to restore outgrowth and branch-
ing of Grn−/− cultures to WT conditions. We also showed
this phenotype can be rescued with the addition of
rPGRN and in fact we were able to stimulate outgrowthand branching beyond normal conditions revealing the
effective neurotrophic abilities of PGRN. The rPGRN
doses exceed the normal range, however, it is difficult to
assess what amount of the rPGRN is truly active or
degraded as a result of protein purification or normal
degradation of the recombinant protein in cell culture
models over time.
Our results suggest that PGRN functions as a neuro-
trophic factor involved in proper neuronal morphology
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Figure 7 Specific missense mutations lack the ability to promote outgrowth and branching in primary hippocampal neurons.
(A) Schematic representation of the GRN gene and location of missense mutations investigated (p.S120Y, p.C139R, p.P248L, p.R432C). (B) Bar
graph quantification of neurite outgrowth of Grn−/− hippocampal neurons treated with 125 nM (10 ug/mL) of wild-type rPGRN-His or missense
rPGRN-His. Data is presented as the mean± SEM. **p< 0.01; ***p< 0.001.
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tein, extracellular PGRN may be responsible for initiat-
ing signaling events that promote neurite development.
For example, we demonstrate that decreased outgrowth
and branching is reversed by the supplementation of
PGRN. Given the variety of Grn−/− models now avail-
able, it would be of great interest to determine if model-
specific characteristics, such as synaptic abnormalities,
altered spines and dendrites, as well as, TDP-43 path-
ology can be rescued with exogenous PGRN treatment.
In the periphery, PGRN is cleaved into mature gran-
ulins by extracellular proteases [15,16], similar to other
neurotrophins, such as nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF), which are
synthesized as precursors and proteolytically cleaved to
form mature neurotrophins [34]. Our data suggest that
rPGRN is being cleaved within primary neuronal cul-
ture media (Figure 3A), therefore we hypothesized that
cleaved PGRN, or granulins, are responsible for indu-
cing its neurotrophic properties. SLPI, a protease in-
hibitor, is known to bind PGRN or elastase to prevent
PGRN cleavage [15,16]. To determine if full length or
cleaved Pgrn is neurotrophic, we treated WT and Grn−/−
primary neurons with and without rSLPI. Our findings
show that rSLPI is able to prevent outgrowth in WT
cultures; however, this is not seen in knockout culturessuggesting rSLPIs specificity for Pgrn. Van Damme et al.
also reported that SLPI abolishes PGRN-enhanced sur-
vival and neurite outgrowth in cortical neurons [11].
More importantly, we show that individual granulins C
and E have the ability to promote neuronal outgrowth,
further emphasizing that PGRN cleavage is required for
neurite outgrowth and branching. While we only tested
granulins C and E, for future studies it will be important
to determine the function of physiologically relevant
granulin products, since previous reports suggest that
they may have differential effects [16].
Given that previous studies determined the C-terminus
tail of PGRN (QLL) binds to the beta-propeller of SORT1
[35], we decided to analyze SORT1 induced uptake of
rPGRN. When generating rPGRN, we tagged our peptide
using a 6 His tag at either the C-terminus (rPGRN-HIS)
or N-terminus (HIS-rPGRN) for purification. His-
rPGRN becomes endocytosed by SORT1 overexpression;
however, we believed the His tag on rPGRN-His would
prevent SORT1 from endocytosing it. Furthermore, we
wanted to determine if these two versions of rPGRN
have similar neurotrophic properties, since only His-
rPGRN interacts with SORT1. Indeed, when we
compared His-rPGRN and rPGRN-His in WT cul-
tures, we observed a very similar dose-dependent
increase in outgrowth suggesting the neurotrophic
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nor to SORT1.
The impact of individual granulins’ neurotrophic func-
tions and our previously mentioned data suggest that
PGRN may be acting independently of SORT1 to pro-
mote neurite outgrowth. Our Sort1−/− cultures exhibit
increased levels of PGRN within the media, a finding that
is consistent with previous reports demonstrating the
ability of SORT1 to regulate PGRN levels [17,35]. These
cultures also display a decrease in neuronal outgrowth,
which may be puzzling considering the increased Pgrn
levels in the media. However, other groups have also
reported this phenomenon and point to SORT1’s inter-
action with tropomyosin-receptor-kinase (Trk) receptors
as the cause. Basically, it was determined that SORT1
is involved in the anterograde transport of Trk recep-
tors to nerve endings, where the receptors induce
trophic signaling [36]. We believe the decreases in
outgrowth in Sort1−/−cultures cultures are caused by
the loss of trophic support resulting from Trk recep-
tor misguidance. Furthermore, we observed that by
adding increasing amounts of PGRN to Sort1−/−cul-
tures, outgrowth and branching increased in a dose-
dependent manner similar to WT neurons. Such
findings further suggest PGRN-induced outgrowth
occurs independent of SORT1.
Pinpointing exactly which receptor is responsible for
PGRN-induced neuronal outgrowth has not yet been
determined and will be the aim of future studies. Tang
et al, recently discovered PGRN also binds to TNFR
[18], and when bound to TNFR, PGRN antagonizes
and prevents downstream TNFα-mediated inflamma-
tory signaling. One could speculate that the loss or
reduced levels of PGRN long-term will enhance cell
death/pro-inflammatory signaling that could be detri-
mental to neuronal viability. It may be possible that
increases in PGRN mitigate the TNFα response to the
extent that we observe neurotrophic effects. In such a
case, excess PGRN may keep the TNFR signaling in
check whereas deficits in PGRN favor a TNFα-
mediated response resulting in reduced outgrowth and
ultimately neuronal death. Given that PGRN promotes
outgrowth independent of SORT1, our data suggest
another receptor(s) is involved in PGRN-induced neur-
onal outgrowth and may be responsible for maintain-
ing neuronal integrity.
Most pathogenic mutations in PGRN result in a loss
of functional PGRN caused by nonsense, splice-site and
frameshift mutations, as well as by mutations that dis-
rupt proper translation and secretion [4-6]. However,
there are several missense mutations of unknown patho-
genicity. Lack of functional data currently restricts our
understanding regarding the possible contribution of
these variants to disease pathogenesis. To furtherelucidate the role missense mutations with undeter-
mined pathogenicity play in causing a loss of neuro-
trophic function, rPGRN containing missense mutations
were generated and analyzed in hippocampal neuronal
cultures. Among the missense mutations studied, two
(p.P248L and p.R432C) were reported to lead to
decreased secretion, and one (p.C139R) reduces PGRN
production, stability and patient plasma levels [7,25,32].
p.S120Y, is unlikely to be pathogenic since it is found in
control patients [37,38] was found to promote neurite
outgrowth similar to WT rPGRN. In contrast, rPGRN
with p.C139R, p.R432C or p.P248L mutations did not
stimulate neurite outgrowth, suggesting that these
mutations adversely affect PGRN function and may be
pathogenic, which would be consistent with previous
genetic studies [39,40].
Conclusions
Taken together, our findings indicate that PGRN is
required for the proper development of neurites in pri-
mary hippocampal neurons. Our results suggest neurite
outgrowth and branching are regulated by extracellular
cleaved granulins. We determined that PGRN induces
outgrowth independent of SORT1, which indicates that
PGRN uses a different receptor to promote neuronal
morphology. While pathogenic mutations cause decreases
in PGRN levels, certain GRN missense mutations abolish
the neurotrophic properties of PGRN, providing a putative




Grn−/− mice have been previously described [27,29].
Sort1−/− mice were generated and previously described
[41-43]. Timed breeding cages of C57/BL/6, Grn−/− and
Sort1−/− were set up for primary neuronal cultures. All
rodent specimens were obtained from animals handled
by procedures approved by the Mayo Clinic Institutional
Animal Care and Use Committee.
Primary neuronal culture
Primary neuronal cultures from hippocampi or cortex
were prepared from postnatal day 1 mouse pups and
stored at 4°C in HIBERNATE™ A media without calcium
(BrainBits), supplemented with B27 (Invitrogen),
0.5 mM GMAX (GIBCO), and gentamicin (GIBCO).
Excised hippocampi or cortex were digested in papain
(2 mg/mL; Fisher Scientific), triturated with a Pasteur
pipet (bore size 0.8–1 mM), centrifuged to collect cell
pellet, and resuspended in Neurobasal A (Invitrogen),
supplemented with B27, GMAX, gentamicin, and bFGF
(Invitrogen). Following determination of cell number,
neurons were plated on poly-D-lysine-coated coverslips
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(seeded at a density of 2.5 × 104 cells/coverslip), or
seeded on poly-D-lysine coated 6-well plates for im-
munoblotting at a seeding density of 3 × 105 cells/well.
Cultures were allowed to mature for 10 days. Media was
changed on the third and seventh days. For experiments
using recombinant protein, cells were treated on day 4
and day 7 after media change.
Recombinant PGRN production
Human progranulin (PGRN) full-length cDNA including
the 5’ signal peptide sequence was subcloned into the
Nhe I and Age I restriction sites of the pcDNA4/V5-
HisA vector such that a 6 His tag was fused at the
carboxyl-terminus of the PGRN sequence. A PGRN
stable cell line was generated by transfecting HEK293
cells with the pcDNA4/PGRN-6His DNA and missense
PGRN-6His DNA in a 6-well culture plate format.
PGRN expression plasmids were sequence verified using
ABI3730 with Big Dye chemistry following manufac-
turers’s protocol (Applied Biosystems, Foster City, CA,
USA). Stable transfectants were selected for 4 weeks in
complete culture medium supplemented with 400 μg/ml
zeocin. Surviving clones were individually picked,
expanded and tested for the PGRN expression. The
clone that secretes the highest level of PGRN protein
into media was used for recombinant PGRN (rPGRN)
production. Standard Ni-NTA (Qiagen) affinity purifica-
tion procedures based on manufacturer’s instruction
were applied to purify the rPGRN protein (Lee et al.
2005).
rAAV1 production
rAAV1-PGRN, rAAV1-SORT1 and rAAV1-GFP was pre-
pared by standard methods. Briefly, AAV vectors expres-
sing PGRN, SORT1 or GFP under the control of the
cytomegalovirus enhancer/chicken β-actin promoter, a
woodchuck post-transcriptional regulatory element, and
the bovine growth hormone, poly(A), were generated by
plasmid transfection with helper plasmids in HEK293T
cells. All plasmids were sequence verified as described
above. Forty-eight hours after transfection, the cells were
harvested and lysed in the presence of 0.5% sodium
deoxycholate and 50 U/ml Benzonase (Sigma, St. Louis,
MO) by freeze thawing, and the virus was isolated using
a discontinuous iodixanol gradient. The genomic titer of
each virus was determined by quantitative PCR.
Immunocytochemistry
Primary neurons on coverslips were fixed in methanol,
permeablized with 0.5% Triton-X-100 in PBS, washed,
blocked in 5% milk-PBS for 1 hour and incubated over-
night in anti-MAP2 (1:500, Sigma-Aldrich) or anti-
progranulin (1:500, Invitrogen) diluted in 5% milk-PBS.Coverslips were then washed and incubated for 2 hours
in goat anti-rabbit Alexa Fluor 568 (1:1000, Molecular
Probes) or goat anti-mouse Alexa Fluor 488 (1:1000,
Molecular Probes). Coverslips were then incubated for 10
minutes in Hoescht 33258 (1:10000, Invitrogen), washed
and mounted onto microscope slides by Fluormount-G
(Southern Biotech).
Image acquisition and quantification
All images were captured using a Zeiss LSM 510 META
confocal microscope. Neuronal morphology measure-
ments were determined using MetaMorph version 7.1
(Molecular Devices, Downingtown, PA). In each experi-
ment, 50–100 neurons sampled from randomly selected
fields were analyzed and repeated in at least three inde-
pendent experiments. Statistical analysis was performed
using GraphPad Prizm 4 by comparing means of differ-
ent groups using Student’s-t test or ANOVA followed by
post hoc Kruskal-Wallis test and Dunn's Multiple Com-
parison Test. Error bars indicate *p< 0.05; **p< 0.01;
***p< 0.001.
Western blot and ELISA
Cells from 6 well plates were lysed in lysis buffer consist-
ing of Co-IP buffer (50 mM Tris–HCl, pH 7.4, 1 M
NaCl, 1% Triton-X-100, 5 mM EDTA) plus 1% SDS,
PMSF, and both a protease and phosphatase inhibitor
mixture. The protein concentration of cell lysates was
measured using a BCA assay (Pierce). Samples were pre-
pared in Laemmli’s buffer, heated for 5 min at 95°C, and
equal amounts of protein were loaded into 10-well 10%
Tris-glycine gels (Novex). After transfer, blots were
blocked with 5% nonfat dry milk in TBST (TBS plus
0.1% TritonX-100) for 1 h, and then blots were incu-
bated with anti-mouse progranulin (1:1000, R&D sys-
tems), anti-human progranulin (1:1000, Invitrogen),
mouse monoclonal GAPDH antibody (1:10000, Biode-
sign) overnight at 4°C. Membranes were washed three
times for 10 min in TBST and then incubated with don-
key anti-rabbit, anti-mouse or anti-sheep IgG conjugated
to horseradish peroxidase (1:2500; Jackson ImmunoRe-
search) for 1 hour. Membranes were washed three times
each for 10 min, and protein expression was visualized
by ECL treatment and exposure to film. Human PGRN
ELISA (R&D Systems) and Mouse Pgrn ELISA (Enzo
Life Sciences) was used according to manufacture proto-
col on media collected from rAAV1-PGRN treated
cultures.
Enzymatic digestion of rPGRN by elastase
30 μg of wild-type recombinant PGRN or mutants PGRN
protein incubated on ice was mixed with reaction buffer
(100 mM Tris–HCl, 300 mM NaCl, pH 7.5) and
0.05 U/ml purified elastase (Athens Research and
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enzyme reaction was initiated by incubation at 37°C.
10 μl of the reaction mixture was sampled every 5
minutes and the reaction was immediately quenched
by adding equal amount of 2 × SDS sample buffer.
The reaction was allowed to proceed until 35 minutes
after time zero. A separate reaction with the addition
of recombinant SLPI at 13.3 μM was also prepared
and preceded for 35 minutes at 37°C. The samples
were analyzed by SDS-PAGE, post-stain with sypro
ruby solution (Sigma) and imaged by a gel doc station
equipped with a UV-transilluminator.
Additional file
Additional file 1: Figure S1. rSLPI prevents rPGRN induced outgrowth
and branching. A-B. Bar graph quantification of normalized total
outgrowth (A) and branching (B) in primary hippocampal cultures
treated with rPGRN± rSLPI. Data is presented as the mean ± SEM.
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